Staphylococcus Aureus Sortase Transpeptidase SrtA: Insight into the Kinetic Mechanism and Evidence for a Reverse Protonation Catalytic Mechanism
Overview
Affiliations
The Staphylococcus aureus transpeptidase SrtA catalyzes the covalent attachment of LPXTG-containing virulence and colonization-associated proteins to cell-wall peptidoglycan in Gram-positive bacteria. Recent structural characterizations of staphylococcal SrtA, and related transpeptidases SrtB from S. aureus and Bacillus anthracis, provide many details regarding the active site environment, yet raise questions with regard to the nature of catalysis and active site cysteine thiol activation. Here we re-evaluate the kinetic mechanism of SrtA and shed light on aspects of its catalytic mechanism. Using steady-state, pre-steady-state, bisubstrate kinetic studies, and high-resolution electrospray mass spectrometry, revised steady-state kinetic parameters and a ping-pong hydrolytic shunt kinetic mechanism were determined for recombinant SrtA. The pH dependencies of kinetic parameters k(cat)/K(m) and k(cat) for the substrate Abz-LPETG-Dap(Dnp)-NH(2) were bell-shaped with pK(a) values of 6.3 +/- 0.2 and 9.4 +/- 0.2 for k(cat) and 6.2 +/- 0.2 and 9.4 +/- 0.2 for k(cat)/K(m). Solvent isotope effect (SIE) measurements revealed inverse behavior, with a (D)2(O)k(cat) of 0.89 +/- 0.01 and a (D)2(O)(k(cat)/K(m)) of 0.57 +/- 0.03 reflecting an equilibrium SIE. In addition, SIE measurements strongly implicated Cys184 participation in the isotope-sensitive rate-determining chemical step when considered in conjunction with an inverse linear proton inventory for k(cat). Last, the pH dependence of SrtA inactivation by iodoacetamide revealed a single ionization for inactivation. These studies collectively provide compelling evidence for a reverse protonation mechanism where a small fraction (ca. 0.06%) of SrtA is competent for catalysis at physiological pH, yet is highly active with an estimated k(cat)/K(m) of >10(5) M(-)(1) s(-)(1).
Tian L, Wang L, Yang F, Zhou T, Jiang H Virulence. 2023; 14(1):2260675.
PMID: 37733916 PMC: 10543341. DOI: 10.1080/21505594.2023.2260675.
Challenges in the use of sortase and other peptide ligases for site-specific protein modification.
Morgan H, Turnbull W, Webb M Chem Soc Rev. 2022; 51(10):4121-4145.
PMID: 35510539 PMC: 9126251. DOI: 10.1039/d0cs01148g.
2-Sulfonylpyrimidines as Privileged Warheads for the Development of Sortase A Inhibitors.
Barthels F, Meyr J, Hammerschmidt S, Marciniak T, Rader H, Ziebuhr W Front Mol Biosci. 2022; 8:804970.
PMID: 35047562 PMC: 8763382. DOI: 10.3389/fmolb.2021.804970.
Shulga D, Kudryavtsev K Molecules. 2021; 26(24).
PMID: 34946760 PMC: 8709105. DOI: 10.3390/molecules26247677.
Yang M, Hu C, Wong C, Liang J, Ko H, He M Front Immunol. 2021; 12:739837.
PMID: 34721406 PMC: 8551676. DOI: 10.3389/fimmu.2021.739837.